Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous

Summary

Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.

Eligibility

Inclusion Criteria:

* Patient over 18
* Patient affiliated to a social security scheme
* Patient who understands French
* Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
* Patient with active cancer:
* Cancer treatment within the last 6 months,
* Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.
* The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).
* Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)

Exclusion Criteria:

* Patients under legal protection
* Patients with concomitant pulmonary embolism
* Patient with proximal or distal deep vein thrombosis
* Patient treated with anticoagulant therapy for another indication
* Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding.
* Patient opposed to participation in research

Conditions3

Browse More Trials